Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial

Authors: Kathleen M Schmainda, Melissa A Prah, Helga Marques, Eunhee Kim, Daniel P Barboriak, Jerrold L Boxerman

Published: 2020-07-10

DOI: 10.1093/neuonc/noaa167

Source: Full article